Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (6 years ago)

Meloxicam Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Meloxicam Tablets, USP 7.5 mg 100 Tablets Rx Only NDC 69097-158-07 Manufactured for: Cipla USA, Inc. 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Affected NDC 69097-0158-07

Compare with the code on your package — it is the most precise check available.

Drug: Meloxicam Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Meloxicam
NDC 69097-0158
7.5 mg/1 Tablet
Oral
Cipla USA Inc. Rx
Recalling firm
Cardinal Health Inc.
NDC code
69097-158-07
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0463-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Meloxicam recalls

See all
Class III · Low risk

Zynrelef (bupivacaine and meloxicam)

Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Terminated Packaging defect Heron Therapeutics, INC. NDC 47426-301-02 D-1335-2022
Class II · Moderate risk

Meloxicam Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0190-2024
Class III · Low risk

Mobic (meloxicam)

Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.

Terminated Labeling / mix-up Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0030-01 D-0007-2018
Class II · Moderate risk

All lidocaine

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1103-2016
Class II · Moderate risk

Meloxicam capsules

Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.

Terminated Cross-contamination South Coast Specialty Compounding, Inc. D-1339-2015

Other recalls by Cardinal Health Inc.

All 2021 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025